N/A N=89 Pediatric Cardiac Output Monitoring Observational Study
Pediatric ALL
Primary: Bias of FloTrac Arterial Pressure Cardiac Output (L/Min) Against Swan Ganz Invasive Cardiac Output — 0.49 L/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=77 Minimally Invasive Cardiac Output Monitoring Device
Cardiac Event
Primary: Establishment of a Dataset to Create an Algorithm to Measure Cardiac Output — 75; 2 Participants
N/A N=33 Noninvasive Measurement of CO Using Impedance Cardiography in Patients With CHD
Congenital Heart Disease
Primary: Mean Difference in Stroke Volume Between CMR and SMIC — 1.7 ml — p=0.47
N/A N=39 Clinical Evaluation of Cardiac Output Estimation Based on Pulse Wave Transit Time
Myocardial Infarction · Myocardial Ischemia
Primary: esCCO (Estimated Continuous Cardiac Output) Monitor — 5.6 liters/minute
N/A N=22 Endothelial Function and Cardiac Output in RV Pacing
Bradycardia
Primary: Endothelial Function Assessed by Flow Mediated Vasodilatation — 1.96; 1.73 EndoPAT index (EnFI)
Phase 4 N=55 Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
Esophageal Diseases · Gastrointestinal Diseases · Disorder of the Genitourinary System
Primary: Length of Hospital Stay (LOS) by Participant
N/A N=60 Ninvasive Cardiac Output Measurements During Cesarean Delivery Under Spinal Anesthesia.
Hypotension During Cesarean Delivery · Spinal Anesthesia
Primary: Percentage of Participants With a Cardiac Output Within and Outside 20% of Baseline Values — 71; 66; 29; 34 percentage of patients — p=0.37
Phase 3 N=26 24 Hour Ambulatory Cardiac Oxygen Consumption
Hypertension
Primary: ACRPP: 24-hour Ambulatory Central Rate-pressure Product (Also Called TTI, CTTI) — 2531; 2824; 2484 mmHg*beats/min — p=0.05
Phase 3 N=261 Impedance Cardiography: Clinical Evaluation of Endotracheal Cardiac Output Monitor (ECOM)
Cardiac Output
Primary: Comparison of ECOM Impedance and Thermodilution Cardiac Output Measurements — 0.31 liters/min
N/A N=10 Blood Volume and Fluid Kinetics in Patients Undergoing Extracorporal Circulation
Blood Volume, Extravasation
Primary: Blood Volume — 4.61 Litre
N/A N=27 Oxygen Consumption-based Assessments of Hemodynamics in Neonates Following Congenital Heart Surgery (Oxy-CAHN Study)
Transposition of the Great Vessels · Hypoplastic Left Heart Syndrome · Oxygen Consumption Based Assessment of Hemodynamics
Primary: Oxygen Consumption — 72; 102 mL oxygen/min/m^2
Phase 4 N=17 Descriptive Study of Cardiac Output During Rehydration With Recombinant Human Hyaluronidase in Pediatrics
Dehydration · Cardiac Output · Pediatrics
Primary: Cardiac Output Trends
N/A N=180 GDT by Cardiac Index Trending Via a Radial Arterial Line in General Surgery
Reduction of Length of Hospitality Stay, Reduction of Perioperative Complications
Primary: Postoperative Complications — 52; 72 numbers of complications
N/A N=657 Measuring Cardiovascular Performance and Blood Flow Using Common But Never Compared Methods.
D012039 · D001775
Primary: Feasibility of Performing Echo, BNP, and VP on Human Subjects. — 657; 236 Participants
N/A N=20 Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation
Node Positive Breast Cancer
Primary: Cardiac MRI Parameters — 0; 0; 0; 0 number of patients
Phase 4 N=76 Cardiovascular Function in COPD Patients
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI) in the 6th Week of Treatment — 2.855; 2.317 Millilitre/ meter^2 (mL/m^2) — p=0.6331
Phase 3 N=201 Risk of Oxygen During Cardiac Surgery Trial
Cardiac Surgery
Primary: Intraoperative Systemic Oxidative Damage — 69; 83 pg/ml
N/A N=15 Right Ventricular Function and Exercise Capacity in Patients With Continuous-flow Left Ventricular Assist Devices
Heart Failure
Primary: Peak Oxygen Uptake — 15 ml/kg/min
Phase 3 N=20 A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)
Cardiac Edema
Primary: Body Weight — -1.68; -2.14 Kg
N/A N=23 Optical Imaging Measurement of Intravascular Solution Efficacy Trial
Peripheral Artery Disease
Primary: Quality of Images — .702; .872; .10; .743 Clear imaging field (CIF) proportion
N/A N=18 Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB)
Complication of Extracorporeal Circulation · Renal Impairment
Primary: Renal Blood Flow (RBF) — 554; 524; 564; 558 ml per minute per 1.73 m2 body surface — p=0.638
N/A N=460 Cerebral Autoregulation Monitoring During Cardiac Surgery
Thoracic Surgery · Cardiopulmonary Bypass
Primary: Composite Neurological Outcome of Clinical Stroke or New Ischemic Brain Lesion on Diffusion Weighted MRI or Neurocognitive Dysfunction 4 to 6 Weeks After Surgery. — 79…
Phase 2 N=10 Coenzyme Q10 in Post-Cardiac Arrest Cerebral Resuscitation
Cardiac Arrest · Sudden Cardiac Arrest
Primary: Prevalence of Low Serum CoQ10 Levels in Cardiac Arrest Patients — 0.706; 0.66 ug/mL
Phase 3 N=110 A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)
Edema, Cardiac
Primary: Body Weight (Amount of Change) — -0.45; -1.54 Kg — p=<0.0001
N/A N=23 Bedside Resources to Gauge Intravascular Volume Status
Hypovolemia · Craniosynostoses
Primary: Utility of Compensatory Reserve Index (CRI) Which Ranges From 0-1 in Order to Predict Fluid Responders From Non-responders — 0.06; 0.05 units on a scale
N/A N=90 Donor After Circulatory Death Heart CAP Trial
Heart Transplant
Primary: Patient Survival — 75 Participants
N/A N=52 Hemosonics- VCU Cardiac Surgery Clinical Study
Cardiopulmonary Bypass
Primary: Clot Time — 4.9; 3.3 min — p=<0.001
N/A N=47 Focused Cardiac Ultrasound
Ventricular Dysfunction · Pericardial Effusion · Valvular Disease
Primary: Number of Patients Detected With Ventricular Dysfunction, Pericardial Effusion, Valvular Disorders, Septal Disorders, and Coronary Anomalies. — 13; 13; 9; 4 Participants
N/A N=31 Daxor - Blood Volume Analysis
Heart Failure · Congestive Heart Failure
Primary: Change in Whole Blood Volume — -1253; -784 mL — p=>0.05
Phase 4 N=55 The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients
Heart Failure
Primary: Myocardial Energetic Efficiency — 48621.3; 50035.7; 50301.0; 52942.8 (((mmhg x ml x bpm) /g)/(1/min))